Sculptor Capital’s ARS Pharmaceuticals SPRY Stock Holding History

Sculptor Capital’s Portfolio SPRY Stock Details SPRY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-77,100	Closed	-$775K	–	418
2025 Q3	$775K	Buy	+77,100	New	+$1.11M	0.01%	259

Other funds holding SPRY

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Sculptor Capital's SPRY Position: Q4 2025 in Review

Sculptor Capital sold out of ARS Pharmaceuticals (SPRY) in Q4 2025, closing a stake of 77,100 shares — an estimated $775K sold.

Sculptor Capital first reported a position in SPRY in Q3 2025 and held it in 1 quarter. The position peaked at $775K in Q3 2025. 189 funds tracked by Wall St. Rank hold SPRY as of Q4 2025.

Sculptor Capital reported no remaining ARS Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Sculptor Capital sold 77,100 ARS Pharmaceuticals shares in Q4 2025, an estimated $775K.
Sculptor Capital first reported a position in ARS Pharmaceuticals in Q3 2025 and held it in 1 quarter.
Sculptor Capital's ARS Pharmaceuticals position peaked at $775K in Q3 2025.
189 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q4 2025.

Based on Sculptor Capital's 13F filing for Q4 2025, filed 13 Feb 2026.